Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Critical Care
Volume 2018 (2018), Article ID 3257215, 3 pages
https://doi.org/10.1155/2018/3257215
Case Report

Angioedema Secondary to IV Tissue Plasminogen Activator Administration for Treatment of Acute Ischemic Stroke

1University of Illinois College of Medicine at Peoria, 1 Illini Dr, Peoria, IL 61605, USA
2Illinois Neurological Institute, OSF Saint Francis Medical Center, Peoria, IL, USA

Correspondence should be addressed to Benjamin Chaucer; ude.ciu@recuahcb

Received 8 January 2018; Revised 9 February 2018; Accepted 14 February 2018; Published 15 April 2018

Academic Editor: Chiara Lazzeri

Copyright © 2018 Benjamin Chaucer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. IV tissue plasminogen activator (tPA) is the treatment of choice for ischemic strokes that present within the treatment window. In the majority of patients, this offers an effective and often life-prolonging treatment in the acute setting. In a rare set of patients treated with IV tPA, side effects can be seen. One rare and potentially dangerous side effect is angioedema. Case Report. We present the case of a patient treated for ischemic stroke who developed angioedema and discuss the etiology and risk factors for this rare, but dangerous side effect. Conclusion. Given the frequent and widespread use of tPA, awareness of the rare life-threatening side effects is paramount. This is of particular importance for practitioners in the acute care setting.